Author

S. Bibi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Organism:virus· 1

Frequent Co-Authors

T. Lambe· 3 shared A. Flaxman· 2 shared A. J. Mentzer· 2 shared A. J. Pollard· 2 shared A. Tuekprakhon· 2 shared D. Crook· 2 shared D. Skelly· 2 shared H. M. E. Duyvesteyn· 2 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

T. Lambe

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Zaire ebolavirus, Sudan ebolavirus, Marburg and Lassa viruses

A. Flaxman, S. Sebastian, S. Appelberg, K. Cha, M. Ulaszewska, J. Purushotham, C. Gilbride, H. Sharpe, A. Spencer, S. Bibi, D. Wright, S. Dowall, L. Easterbrook, S. Findlay-Wilson, S. Gilbert, , T. Lambe

This paper develops a multi-pathogen vaccine targeting Zaire ebolavirus, Sudan ebolavirus, Marburg and Lassa viruses, showing strong immunogenicity and protective efficacy in animal models.

bioRxiv · Nov 3, 2023 · PreprintImmunology

Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum

A. Tuekprakhon, J. Huo, R. Nutalai, A. Dijokaite-Guraliuc, D. Zhou, H. M. Ginn, M. Sekvaraj, C. Liu, A. J. Mentzer, P. Supasa, H. M. E. Duyvesteyn, R. Das, D. Skelly, T. G. Ritter, A. Amini, , G. R. Screaton

This study shows that BA.4 and BA.5 variants are more resistant to neutralization by vaccine and BA.1 immune sera compared to BA.1 and BA.2.

bioRxiv · May 21, 2022 · PreprintMicrobiology

Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2

W. - Dejnirattisai, D. - Zhou, P. - Supasa, C. - Liu, A. J. Mentzer, H. M. Ginn, Y. - Zhao, H. M. E. Duyvesteyn, A. Tuekprakhon, R. Nutalai, B. - Wang, G. C. Paesen, C. - Lopez-Camacho, J. - Slon-Campos, T. Walter, , Barne

This study compares antibody resistance of SARS-CoV-2 variants P.1, B.1.351, and B.1.1.7, finding P.1 is less resistant to antibodies despite similar ACE2 binding mutations.

bioRxiv · Mar 12, 2021Microbiology